References
- Ghadir MR, Ebrazeh A, Khodadadi J, Zamanlu M, Shams S, Nasiri M, et al. The COVID-19 outbreak in Iran: the first patient with a definite diagnosis. Arch Iran Med. 2020;23(7):503–504. doi:https://doi.org/10.34172/aim.2020.48.
- Rassouli M, Ashrafizadeh H, Shirinabadi Farahani A, Akbari ME. COVID-19 management in Iran as one of the most affected countries in the world: advantages and weaknesses. Front Public Health. 2020;8:510. doi:https://doi.org/10.3389/fpubh.2020.00510.
- Heidari M, Jafari H. Challenges of COVID-19 vaccination in Iran: in the fourth wave of pandemic spread. Prehosp Disaster Med. 2021;36(5):659–660. doi:https://doi.org/10.1017/S1049023X21000777.
- Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783–791. doi:https://doi.org/10.1158/2159-8290.Cd-20-0422.
- Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–337. doi:https://doi.org/10.1016/S1470-2045(20)30096-6.
- Nematshahi M, Soroosh D, Neamatshahi M, Attarian F, Rahimi F. Factors predicting readmission in patients with COVID-19. BMC Res Notes. 2021;14(1):374. doi:https://doi.org/10.1186/s13104-021-05782-7.
- Lee LYW, Cazier J-B, Angelis V, Arnold R, Bisht V, Campton NA, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395(10241):1919–1926. doi:https://doi.org/10.1016/S0140-6736(20)31173-9.
- Lee LYW, Cazier JB, Starkey T, Briggs SEW, Arnold R, Bisht V, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020;21(10):1309–1316. https://doi.org/10.1016/S1470-2045(20)30442-3.
- Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):e737–e745. doi:https://doi.org/10.1016/S2352-3026(20)30251-9.
- Sood N, Simon P, Ebner P, Eichner D, Reynolds J, Bendavid E, et al. Seroprevalence of SARS-CoV-2-specific antibodies among adults in Los Angeles county, California, on April 10–11, 2020. JAMA. 2020;323(23):2425–2427. doi:https://doi.org/10.1001/jama.2020.8279.
- Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;396(10247):313–319. doi:https://doi.org/10.1016/S0140-6736(20)31304-0.
- Xu X, Sun J, Nie S, Li H, Kong Y, Liang M, et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. Nat Med. 2020;26(8):1193–1195. doi:https://doi.org/10.1038/s41591-020-0949-6.
- Cabezón-Gutiérrez L, Custodio-Cabello S, Palka-Kotlowska M, Oliveros-Acebes E, García-Navarro MJ, Khosravi-Shahi P. Seroprevalence of SARS-CoV-2-specific antibodies in cancer outpatients in Madrid (Spain): a single center, prospective, cohort study and a review of available data. Cancer Treat Rev. 2020;90:102102. doi:https://doi.org/10.1016/j.ctrv.2020.102102.
- Cantini L, Bastianelli L, Lupi A, Pinterpe G, Pecci F, Belletti G, et al. Seroprevalence of SARS-CoV-2-specific antibodies in cancer patients undergoing active systemic treatment: a single-center experience from the Marche region. JCM. 2021;10(7):1503. doi:https://doi.org/10.3390/jcm10071503.
- Ariamanesh M, Porouhan P, PeyroShabany B, Fazilat-Panah D, Dehghani M, Nabavifard M, et al. Immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with malignancy. Cancer Invest. 2021;1–12. doi:https://doi.org/10.1080/07357907.2021.1992420.
- Elkrief A, Desilets A, Papneja N, Cvetkovic L, Groleau C, Lakehal YA, et al. High mortality among hospital-acquired COVID-19 infection in patients with cancer: a multicentre observational cohort study. Eur J Cancer. 2020;139:181–7. doi:https://doi.org/10.1016/j.ejca.2020.08.017.
- de Joode K, Dumoulin DW, Tol J, Westgeest HM, Beerepoot LV, van den Berkmortel F, et al. Dutch Oncology COVID-19 consortium: outcome of COVID-19 in patients with cancer in a nationwide cohort study. Eur J Cancer. 2020;141:171–184. doi:https://doi.org/10.1016/j.ejca.2020.09.027.
- Saini KS, Tagliamento M, Lambertini M, McNally R, Romano M, Leone M, et al. Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies. Eur J Cancer. 2020;139:43–50. doi:https://doi.org/10.1016/j.ejca.2020.08.011.
- Shahidsales S, Aledavood SA, Joudi M, Molaie F, Esmaily H, Javadinia SA. COVID‐19 in cancer patients may be presented by atypical symptoms and higher mortality rate, a case‐controlled study from Iran. Cancer Rep. 2021;e1378. doi:https://doi.org/10.1002/cnr2.1378.
- Taghizadeh-Hesary F, Porouhan P, Soroosh D, PeyroShabany B, Shahidsales S, Keykhosravi B, et al. COVID-19 in cancer and non-cancer patients. Int J Cancer Manag. 2021;14(4). doi:https://doi.org/10.5812/ijcm.110907.
- Thakkar A, Pradhan K, Jindal S, Cui Z, Rockwell B, Shah AP, et al. Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy. Nat Cancer. 2021;2(4):392–399. doi:https://doi.org/10.1038/s43018-021-00191-y.
- Brar G, Pinheiro LC, Shusterman M, Swed B, Reshetnyak E, Soroka O, et al. COVID-19 severity and outcomes in patients with cancer: a matched cohort study. J Clin Oncol. 2020;38(33):3914–3924. doi:https://doi.org/10.1200/jco.20.01580.
- Lièvre A, Turpin A, Ray-Coquard I, Le Malicot K, Thariat J, Ahle G, et al. Risk factors for coronavirus disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: a French nationwide cohort study (GCO-002 CACOVID-19). Eur J Cancer. 2020;141:62–81. doi:https://doi.org/10.1016/j.ejca.2020.09.035.
- Poustchi H, Darvishian M, Mohammadi Z, Shayanrad A, Delavari A, Bahadorimonfared A, et al. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study. Lancet Infect Dis. 2021;21(4):473–481. doi:https://doi.org/10.1016/s1473-3099(20)30858-6.
- Arab M, Noei Teymoordash s, Talayeh M, Ghavami B, Javadi A, Nouri B. Evaluation of serologic changes of IgG and IgM antibodies associated with SARS-COV-2 in cancer patients: a cohort seroprevalence study. Asian Pac J Cancer Prev. 2021;22(6):1667–1670. doi:https://doi.org/10.31557/apjcp.2021.22.6.1667.
- Ladoire S, Goussot V, Redersdorff E, Cueff A, Ballot E, Truntzer C, et al. Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: the canSEROcov study. Eur J Cancer. 2021;148:359–370. doi:https://doi.org/10.1016/j.ejca.2021.02.027.
- Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, et al. Performance characteristics of the abbott architect SARS-CoV-2 IgG assay and seroprevalence in Boise, Idaho. J Clin Microbiol. 2020;58(8):e00941–20. doi:https://doi.org/10.1128/JCM.00941-20.
- Manalac J, Yee J, Calayag K, Nguyen L, Patel PM, Zhou D, et al. Evaluation of abbott anti-SARS-CoV-2 CMIA IgG and euroimmun ELISA IgG/IgA assays in a clinical lab. Clin Chim Acta. 2020;510:687–690. doi:https://doi.org/10.1016/j.cca.2020.09.002.
- Chew KL, Tan SS, Saw S, Pajarillaga A, Zaine S, Khoo C, et al. Clinical evaluation of serological IgG antibody response on the abbott architect for established SARS-CoV-2 infection. Clin Microbiol Infect. 2020;26(9):1256.e9–e11. doi:https://doi.org/10.1016/j.cmi.2020.05.036.
- Garde-Noguera J, Fernández-Murga ML, Giner-Bosch V, Dominguez-Márquez V, Sánchez JG, Soler-Cataluña JJ, et al. Impact of SARS-CoV-2 infection on patients with cancer: retrospective and transversal studies in Spanish population. Cancers. 2020;12(12):3513. doi:https://doi.org/10.3390/cancers12123513.
- Liu T, Zeng G, Tao H, Shi Y, Wang T, Liu T, et al. Low prevalence of IgG antibodies to SARS-CoV-2 in cancer patients with COVID-19. Int J Cancer. 2020;147(11):3267–3269. doi:https://doi.org/10.1002/ijc.33148.
- COVID-19 Vaccines & Patients with Cancer. US: American Society of Clinical Oncology; 2021. Available from: https://www.asco.org/covid-resources/vaccines-patients-cancer
- Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, et al. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol. 2021;18(5):313–319. doi:https://doi.org/10.1038/s41571-021-00487-z.